Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • news
  • Page 32
FET-rearranged Myoepithelial Tumors: Why Epigenetics Demands a Shift from Carcinoma to Sarcoma Classification
Posted innews Oncology Pathology & Lab Medicine

FET-rearranged Myoepithelial Tumors: Why Epigenetics Demands a Shift from Carcinoma to Sarcoma Classification

Posted by MedXY By MedXY 01/12/2026
A landmark study reveals that FET-rearranged myoepithelial tumors are epigenetically distinct from PLAG1-rearranged salivary and adnexal variants, suggesting they are closer to sarcomas than carcinomas, with significant clinical implications for pediatric and young adult oncology.
Read More
Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients
Posted inGastroenterology news Oncology

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients

Posted by MedXY By MedXY 01/12/2026
A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial exclusion criteria.
Read More
MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer
Posted innews Oncology Urology

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer

Posted by MedXY By MedXY 01/12/2026
A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for patient selection when tissue is limited.
Read More
Posted innews Oncology

Biomarker-Driven Precision in Low-Grade Serous Ovarian Cancer: pERK and MAPK Mutations as Predictors of Trametinib Efficacy

Posted by Zhang Paul By Zhang Paul 01/12/2026
Highlights High tumour pERK expression (histoscore >140) is a significant predictor of prolonged progression-free survival…
Read More
Beyond PD-1: The Rise of Anti-LAG-3 Antibody LBL-007 in Fighting Nasopharyngeal Carcinoma
Posted innews Oncology Otorhinolaryngology

Beyond PD-1: The Rise of Anti-LAG-3 Antibody LBL-007 in Fighting Nasopharyngeal Carcinoma

Posted by MedXY By MedXY 01/11/2026
Recent clinical trials reveal that LBL-007, a novel anti-LAG-3 antibody, significantly enhances treatment outcomes for advanced nasopharyngeal carcinoma when combined with PD-1 inhibitors, marking a potential shift in the standard of care for immunotherapy.
Read More
AHR Inhibition with IK-175: A New Frontier in Overcoming Checkpoint Resistance in Urothelial Carcinoma
Posted innews Oncology Urology

AHR Inhibition with IK-175: A New Frontier in Overcoming Checkpoint Resistance in Urothelial Carcinoma

Posted by MedXY By MedXY 01/11/2026
This Phase 1/1b study demonstrates that IK-175, an oral AHR inhibitor, is safe and clinically active in PD-1-refractory urothelial carcinoma, showing target engagement and preliminary efficacy both as monotherapy and in combination with nivolumab.
Read More
FDG-PET-Guided Dose De-escalation: A New Standard for HPV-Positive Oropharyngeal Cancer?
Posted innews Oncology Otorhinolaryngology

FDG-PET-Guided Dose De-escalation: A New Standard for HPV-Positive Oropharyngeal Cancer?

Posted by MedXY By MedXY 01/11/2026
A multi-center phase II trial demonstrates that mid-treatment FDG-PET imaging can safely identify patients with HPV+ oropharyngeal cancer for radiation dose reduction, resulting in non-inferior tumor control and significantly improved quality of life.
Read More
Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?
Posted innews Oncology

Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?

Posted by MedXY By MedXY 01/11/2026
The CARABELA trial suggests that while neoadjuvant abemaciclib plus letrozole did not meet the threshold for similarity to chemotherapy in highly proliferative HR+/HER2- breast cancer, it remains a viable alternative for patients with lower genomic risk or moderate proliferation indices.
Read More
Denosumab Shows Insufficient Activity in Recurrent Osteosarcoma: Results from a Children’s Oncology Group Phase 2 Trial
Posted innews Oncology Pediatrics

Denosumab Shows Insufficient Activity in Recurrent Osteosarcoma: Results from a Children’s Oncology Group Phase 2 Trial

Posted by MedXY By MedXY 01/11/2026
A Phase 2 trial by the Children's Oncology Group found that denosumab, despite its success in other bone-related conditions, failed to meet efficacy benchmarks for recurrent or refractory osteosarcoma, showing no objective responses in patients with measurable disease.
Read More
Neoadjuvant Nivolumab plus Chemotherapy Redefines Pathologic Response in Locally Advanced Resectable Head and Neck Cancer
Posted innews Oncology Otorhinolaryngology

Neoadjuvant Nivolumab plus Chemotherapy Redefines Pathologic Response in Locally Advanced Resectable Head and Neck Cancer

Posted by MedXY By MedXY 01/11/2026
This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally advanced, resectable disease.
Read More
KEYLYNK-009: Is Olaparib Plus Pembrolizumab a Viable Maintenance Strategy in Metastatic Triple-Negative Breast Cancer?
Posted innews Oncology

KEYLYNK-009: Is Olaparib Plus Pembrolizumab a Viable Maintenance Strategy in Metastatic Triple-Negative Breast Cancer?

Posted by MedXY By MedXY 01/11/2026
The KEYLYNK-009 trial investigated pembrolizumab plus olaparib as maintenance therapy for metastatic TNBC. While it did not meet primary PFS or OS endpoints compared to chemotherapy, the combination showed a favorable trend in BRCA-mutated patients and a potentially better safety profile.
Read More
Precision Management of KRAS G12V-Mutated NSCLC: Molecular Insights and Therapeutic Strategies
Posted innews Oncology Respiratory

Precision Management of KRAS G12V-Mutated NSCLC: Molecular Insights and Therapeutic Strategies

Posted by MedXY By MedXY 01/11/2026
This article synthesizes recent findings on the KRAS G12V mutation in non-small cell lung cancer, highlighting its unique molecular profile, strong association with smoking, and superior response to immunotherapy compared to traditional chemotherapy.
Read More
INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC
Posted innews Oncology Otorhinolaryngology

INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC

Posted by MedXY By MedXY 01/11/2026
The Phase II/III INDUCE-3 trial was terminated early after the ICOS agonist feladilimab plus pembrolizumab failed to show superiority over pembrolizumab monotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma, with survival data actually favoring the control group.
Read More
Genomic Evolution of Breast Cancer: How Acquired Gene Fusions Drive Metastatic Progression and Treatment Resistance
Posted innews Oncology

Genomic Evolution of Breast Cancer: How Acquired Gene Fusions Drive Metastatic Progression and Treatment Resistance

Posted by MedXY By MedXY 01/11/2026
A multi-omics analysis from the AURORA program reveals that metastatic breast cancer carries a significantly higher burden of gene fusions than primary tumors. Acquired fusions, particularly involving ESR1, are linked to genomic instability and poor clinical outcomes.
Read More
Erdafitinib Yields 55% Response Rate in FGFR-Altered Advanced Cholangiocarcinoma: Insights from a Pooled Phase 2 Analysis
Posted inGastroenterology news Oncology

Erdafitinib Yields 55% Response Rate in FGFR-Altered Advanced Cholangiocarcinoma: Insights from a Pooled Phase 2 Analysis

Posted by MedXY By MedXY 01/11/2026
A pooled analysis of the RAGNAR and LUC2001 trials demonstrates that erdafitinib provides a robust objective response rate of 55% and a median overall survival of 18.1 months in pretreated patients with FGFR-altered advanced cholangiocarcinoma.
Read More
MAPK Pathway Mutations Drive Resistance to Ivosidenib in IDH1-Mutant Cholangiocarcinoma by Blunting Interferon Signaling
Posted inGastroenterology news Oncology

MAPK Pathway Mutations Drive Resistance to Ivosidenib in IDH1-Mutant Cholangiocarcinoma by Blunting Interferon Signaling

Posted by MedXY By MedXY 01/11/2026
A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing critical interferon-gamma-mediated antitumor responses.
Read More
Eribulin Demonstrates Clinical Efficacy in Taxane-Pretreated Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Posted innews Oncology

Eribulin Demonstrates Clinical Efficacy in Taxane-Pretreated Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

Posted by MedXY By MedXY 01/11/2026
A Phase 2 study reveals that eribulin, a non-taxane microtubule inhibitor, provides meaningful objective responses and disease stability in patients with rare vascular sarcomas, including those previously treated with taxanes.
Read More
Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer
Posted inGastroenterology news Oncology

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

Posted by MedXY By MedXY 01/11/2026
A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.
Read More
Resveratrol and Type 2 Diabetes: Does the Red Wine Compound Really Control Blood Sugar?
Posted inDiabetes & Endocrinology Internal Medicine news

Resveratrol and Type 2 Diabetes: Does the Red Wine Compound Really Control Blood Sugar?

Posted by MedXY By MedXY 01/11/2026
A rigorous clinical trial reveals that five weeks of resveratrol supplementation does not improve blood sugar, GLP-1 levels, or gastric emptying in patients with type 2 diabetes.
Read More
Dietary Phytomix Dibifree Reshapes T2D Management by Modulating the Gut-Pancreas-Adipose-Immune Axis
Posted inDiabetes & Endocrinology Internal Medicine news

Dietary Phytomix Dibifree Reshapes T2D Management by Modulating the Gut-Pancreas-Adipose-Immune Axis

Posted by MedXY By MedXY 01/11/2026
A randomized trial demonstrates that Dibifree, a novel dietary phytomix, improves HbA1c and adiposity in T2D patients by enhancing GLP-1 activity and modulating immune responses.
Read More

Posts pagination

Previous page 1 … 30 31 32 33 34 … 185 Next page
  • Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care
  • Synergistic Benefits of Plant-Based Lifestyles and Genetic Resilience: A New Paradigm for Coronary Heart Disease Prevention
  • ACTA2 Pathogenic Variants: Unmasking the Link Between Smooth Muscle Cell Stress and Early-Onset Atherosclerosis
  • Prognostic Significance of Dephospho-Uncarboxylated Matrix Gla-Protein in Heart Failure: Insights into Vascular Calcification and Therapeutic Implications
  • Refining ARVC Risk Stratification: Does Left Ventricular Late Gadolinium Enhancement Add Incremental Value to Clinical Risk Calculators?
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in